Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Aptahem

0.85 SEK

-16.06 %

Less than 1K followers

APTA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-16.06 %
-18.47 %
-44.85 %
-31.99 %
-39.65 %
-27.99 %
-96.97 %
-99.22 %
-99.83 %

Aptahem operates in the pharmaceutical industry. The company develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's lead candidate is being developed as an emergency drug intended to prevent the onset of life-threatening organ and tissue damage in patients suffering from sepsis. A large part of the research is carried out in collaboration with partners in the industry. The company was founded in 2014 and is headquartered in Malmö.

Read more
Market cap
17.87M SEK
Turnover
13.36K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12/2
2026

Annual report '25

27/3
2026

General meeting '26

All
Press releases
3rd party
ShowingAll content types
Regulatory press release12/5/2025, 7:52 AM

Aptahem erhåller patentskydd i Kina för patentfamilj 2

Aptahem
Regulatory press release12/5/2025, 7:52 AM

Aptahem receives patent protection in China for patent family 2

Aptahem
Regulatory press release11/28/2025, 7:45 AM

Aptahems delårsrapport 2025-07-01 till 2025-09-30

Aptahem

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release11/6/2025, 1:15 PM

Aptahems valberedning inför årsstämman 2026

Aptahem
Press release10/30/2025, 8:56 AM

Aptahems webbinarium "Strategic direction and planned US listing" nu tillgängligt

Aptahem
Press release10/30/2025, 8:56 AM

Aptahem's webinar "Strategic Direction and Planned US Listing" now available

Aptahem
Press release10/22/2025, 10:49 AM

Aptahem bjuder in till engelskspråkigt webbinarium om strategisk inriktning och planerad USA-notering

Aptahem
Press release10/22/2025, 10:49 AM

Aptahem Announces English-Language Webinar on Strategic Direction and Planned U.S. Listing

Aptahem
Press release10/21/2025, 6:45 AM

Aptahem: Newsletter October 2025

Aptahem
Press release10/21/2025, 6:45 AM

Aptahem: Nyhetsbrev oktober 2025

Aptahem
Regulatory press release10/2/2025, 1:12 PM

Aptahems företrädesemission är registrerad - omvandling av BTA till aktier

Aptahem
Regulatory press release10/2/2025, 6:42 AM

Aptahem avslutade likviditetsgaranti med Mangold per den 24 september 2025

Aptahem
Regulatory press release9/26/2025, 9:10 AM

Aptahem offentliggör slutligt utfall i bolagets företrädesemission av aktier

Aptahem
Press release9/25/2025, 1:19 PM

Aptahem går vidare med fokus på USA-noteringsstrategi, regulatoriska framsteg och partnerengagemang efter utfall i företrädesemission

Aptahem
Press release9/25/2025, 1:19 PM

Aptahem moves forward with focus on U.S. listing strategy, regulatory progress, and partner engagement following outcome of rights issue

Aptahem
Regulatory press release9/24/2025, 3:24 PM

Aptahem offentliggör preliminärt utfall i företrädesemission

Aptahem
Press release9/23/2025, 10:28 AM

Aptahems webbinarium "Aptahem om strategisk riktning och planerad USA-notering" nu tillgängligt

Aptahem
Regulatory press release9/23/2025, 9:53 AM

Aptahem receives Notice of Allowance in China for patent family 2

Aptahem
Regulatory press release9/23/2025, 9:53 AM

Aptahem erhåller preliminärt patentgodkännande i Kina för patentfamilj 2

Aptahem
Press release9/19/2025, 9:48 AM

Mangold Insights Aptahem-analys: USA-notering ska säkra framtida studier

Aptahem
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.